Andrew has experience of patent litigation, with a focus on pharmaceutical and diagnostic patent litigation. In this context he has worked for major global pharmaceutical companies on significant cases in the High Court and Court of Appeal, as well as advising on European and global patent litigation strategy, working with law firms from around the world.
He has attended and advised on strategy in relation to opposition hearings at the European Patent Office in Munich (both revoking and defending patents) and has also attended and advised on strategy in relation to significant patent trials in Norway, Canada and Australia.
Andrew has attended week-long experiments in the context of UK litigation and has been involved in letters of request to the English courts in connection with patent proceedings in the United States.
He has also been involved in work relating to the European Unified Patent Court.
Recent experience includes advising:
- Gilead in multi-jurisdictional patent litigation, including UK actions in the High Court and the Court of Appeal concerning Gilead's ground-breaking drug Sovaldi for the treatment of HCV and on other European matters.
- Ariosa on a multi-jurisdictional patent dispute concerning its Harmony® non-invasive prenatal genetic test, including a defence of patent infringement proceedings in the UK High Court.
- Roche on a number of high-value matters, including UK patent proceedings in relation to Xeloda.
- Biogen on a multi-jurisdictional patent dispute concerning its multiple sclerosis product Tecfidera®
Prior to his career in law, Andrew completed a four year degree in Natural Sciences graduating with a first class BA/MSci from the University of Cambridge. His final year included a research project in synthetic organic chemistry with the Paterson group. Andrew completed the University of Oxford Postgraduate Diploma in Intellectual Property Law and Practice, being awarded a Distinction in July 2013.
Andrew is admitted as a solicitor in England & Wales and in Ireland.